Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country
| Autor: | Roongrawee Sriaksorn, Piyada Angsuwatcharakon, Terapong Tantawichien, Natchaya Ratananpinit, Nattasri Raksahket, Sutee Yoksan, Wachiraporn Saengseesom |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Asia
Adolescent Rabies 030231 tropical medicine Booster dose Antibodies Viral medicine.disease_cause 03 medical and health sciences 0302 clinical medicine Rabies vaccine Chlorocebus aethiops medicine Animals Humans 030212 general & internal medicine Japanese encephalitis vaccine Child Encephalitis Japanese Neutralizing antibody General Veterinary General Immunology and Microbiology biology Japanese Encephalitis Vaccines business.industry Rabies virus Public Health Environmental and Occupational Health Japanese encephalitis medicine.disease Antibodies Neutralizing Virology Vaccination Infectious Diseases Rabies Vaccines biology.protein Molecular Medicine Pre-Exposure Prophylaxis business medicine.drug |
| Zdroj: | Vaccine. 38:5015-5020 |
| ISSN: | 0264-410X |
| Popis: | Background Reducing the number of doses required for pre-exposure prophylaxis (PrEP) would make it more feasible and cost-effective to implement in children at the highest risk of rabies exposure in Asia. We studied immune response of 2-site intradermal (ID) injection of rabies vaccine on days 0 and 28 for rabies PrEP simultaneously administrated with live-attenuated Japanese encephalitis chimeric virus vaccine (JE-CV) for children living in endemic area. Research design and methods Seronegative children (n = 49) aged 12-16 months were randomized 2:1 into two groups: Group A subjects were vaccinated with 0.1-mL ID injection of purified Vero cell rabies vaccine (PVRV), each at two sites on day (D) 0 and D28; Group B subjects were vaccinated with conventional 0.5-mL intramuscular PVRV on D0, D7 and D28. Both groups received one dose of JE-CV subcutaneously on D0 and D365. Rabies virus neutralizing antibody (RVNA) titers were measured on D0, D42 and D365 after vaccination; Japanese Encephalitis (JE) neutralizing antibody titers were determined on D0, D42, D365 and D379. Results All children had RVNA ≥ 0.5 IU/mL on D42 (geometric mean titers [GMTs] of RVNA 14.35 IU/mL [Group A] and 14.83 IU/mL [Group B], p > 0.05]). On D365, RVNA GMTs of subjects in group A and B were 1.50 IU/mL and 2.00 IU/mL (p > 0.05), respectively. All children had seroprotection following booster dose of JE-CV. There were no vaccine-related SAEs observed. Conclusion The 2-site ID PrEP with PVRV on days 0 and 28 co-administrated with JE-CV are safe and immunogenic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect